SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending as traders weigh risk-on sentiment against rising bond yields and anticipate potential outcomes from US-China trade discussions. The community is closely watching for any signs of a "deal," with some suggesting that any positive news, even minor, could trigger a rally. Bullish sentiment remains despite mixed earnings reports from major tech companies and uncertainty surrounding future rate cuts.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as traders digest news from the Trump-Xi meeting and await key earnings reports from major tech companies. Community chatter revolves around potential market reactions, with some anticipating a pullback and others expecting continued upward momentum. Sentiment appears mixed as participants analyze the implications of the meeting's outcome and upcoming financial results in the tech sector.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending, fueled by community enthusiasm and discussions around its potential. The community is rallying behind the coin, emphasizing a shared vision and active development, while also celebrating its association with the $WAGMI meme. Conversations also highlight the coin's presence on the Solana blockchain and its potential for future growth.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Despite strong revenue growth, Meta Platforms is trending due to concerns about increased spending on AI and infrastructure, as well as a one-time tax charge impacting earnings. The community is debating whether the dip represents a buying opportunity or signals deeper issues with the company's investment strategy. Discussions also involve comparing Meta's situation and valuation to other tech giants like Google and Microsoft.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as it approaches a new all-time high, with many anticipating a continued climb and eyeing the $200 mark. Bullish sentiment is fueled by the company's AI prospects, its partnership with NVIDIA, and speculation around a potential stock split. However, some community members express concerns about the company's high valuation and potential for a pullback.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as community members discuss its potential, particularly around new projects and meme coins built on the network. The launch of a Solana ETF is also generating excitement. Despite some volatility, there's a strong sense of optimism and community support driving conversation around the cryptocurrency.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending as investors analyze the implications of its recent earnings report, particularly its significant AI spending and Azure cloud growth. Community discussions revolve around whether the company's investments will translate to long-term gains, with some expressing concerns about near-term guidance and profitability, while others see it as a buying opportunity for a tech leader.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle ($CMG) is trending as investors react to concerns about slowing sales and rising costs highlighted in the upcoming earnings report, with some analysts lowering price targets. The community is debating whether the stock is oversold, the impact of economic pressures on consumer spending at Chipotle, and the effectiveness of the current CEO. Some traders are also discussing portion sizes and pricing relative to competitors such as CAVA.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending as investors discuss its recent $900 million convertible note offering and its implications for the company's AI and data center expansion plans. Community members are debating whether the offering represents a strong vote of confidence or potential dilution, with some highlighting the favorable terms and Google's backing as bullish signals. The broader context involves TeraWulf's shift towards high-performance computing and AI, positioning it within the competitive landscape of clean energy and data center operations.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending as investors analyze its potential following strong Q3 earnings, with revenue exceeding expectations and AI advancements driving growth. The community is focused on the company's increased capital expenditures and the potential impact of AI on its search revenues, considering whether GOOGL can reach new price targets. Some analysts see significant upside, citing the strength of Google's ad and AI strategy relative to peers.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Limb-girdle muscular dystrophy type 2I/R9 patients treated with BBP-418 in a late-stage study demonstrated improvements in motor and pulmonary function at 12 months, the company said.&nbsp;</li><li>BridgeBio now intends to file a new drug application for the therapy's approval in the first half of 2026. &nbsp;</li></ul>BridgeBio Pharma, Inc. (BBIO) on Monday announced that limb-girdle muscular dystrophy type 2I/R9 patients treated with BBP-418 in a late-stage study demonstrated improvements in motor and pulmonary function at 12 months.Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) is a rare, inherited disorder leading to progressive weakness and wasting of the arm and leg muscles, commonly later accompanied by pulmonary muscle and cardiac muscle involvement. It is caused by mutations in the FKRP gene, impairing glycosylation of alpha-dystroglycan (αDG), a protein associated with stabilizing muscle cells.<h2 class="st-heading-2">Other Trial Observations</h2>BridgeBio<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/27/3174417/0/en/BridgeBio-Reports-Positive-Phase-3-Results-for-Small-Molecule-BBP-418-in-LGMD2I-R9-FORTIFY-Study.html"> said</a> that glycosylated αDG increased by 1.8x from baseline at 3 months, whereas the placebo group showed little change. These improvements were sustained at 12 months in BBP-418-treated individuals, it further added.Furthermore, an average reduction of 82% from baseline in serum creatine kinase, a marker of muscle damage, was observed in BBP-418-treated individuals, it added.<h2 class="st-heading-2">Drug Safety</h2>BBP-418 was well-tolerated in the study with no new or unexpected safety findings observed, the company said. Overall, interim analysis data are supportive of a favorable risk-benefit profile for BBP-418, the company said.The company now intends to file a new drug application for approval of the therapy in the first half of 2026. It plans to engage with the U.S. Food and Drug Administration to discuss data from its studies later this year.<a href="https://stocktwits.com/symbol/BBIO">BBIO shares</a> traded 9% higher in the pre-market session at the time of writing. On Stocktwits, retail sentiment around BBIO jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.BBIO stock has nearly doubled this year.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/neumora-therapeutics-experimental-drug-demonstrates-weight-loss-in-preclinical-studies/cLG030zR3ML">Neumora Therapeutics’ Experimental Drug Demonstrates Weight Loss in Preclinical Studies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

BBIO Stock Soars After Experimental Drug Shows Improvement In Inherited Muscle Disorder In Late-stage Trial

BridgeBio (BBIO) now intends to file a new drug application for the therapy's approval in the first half of 2026.

Equity

<ul class="summary-bullets"><li>Retail sentiment on Krispy Kreme stock jumped to ‘extremely bullish’ territory from ‘bearish’ compared to a day ago on Stocktwits.</li><li>Morgan Stanley kept its ‘Underweight’ rating on the stock with a $2.5 price.</li><li>Krispy Kreme was the top-performing stock, despite a broader slowdown in overall sector trends, Morgan Stanley said.</li></ul>Krispy Kreme (DNUT) stock traded above the 200-day moving average (DMA) for the first time since November 2024 and experienced an over 8,200% increase in retail user message count over 24 hours on Stocktwits, as of Wednesday morning, following a Morgan Stanley note that it was the top-performing restaurant stock in the third quarter.The stock touched a high of $5.11 on Wednesday versus the 200-DMA level of $4.66 earlier in the day. However, it had pared some of the gains as of the time of writing.Retail sentiment on Krispy Kreme jumped to ‘extremely bullish’ territory from ‘bearish’ compared to a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.<h2 class="st-heading-2">Analyst Take On DNUT</h2>Morgan Stanley kept its ‘Underweight’ rating and a $2.5 price target on Krispy Kreme, according to MT Newswires. The firm noted that Krispy Kreme was the top-performing stock, despite a broader slowdown in overall sector trends.“Restaurants as a whole have performed poorly as industry data show a slowdown beginning in September,” Morgan Stanley said.<a href="https://stocktwits.com/symbol/DNUT">Shares of Krispy Kreme</a> have lost over 60% of their value in the last 12 months.<h2 class="st-heading-2">Recent Developments At Krispy Kreme</h2>Last week, Krispy Kreme announced the opening of its first store in Madrid, Spain, on October 2, 2025, through a minority interest joint venture with Glaseados Originales S.L. The company said that additional shop openings in Brazil and Uzbekistan are planned before the end of 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/beyond-meat-stock-skyrockets-60-today-meme-stock-frenzy-intensifies-after-etf-inclusion-amid-surging-retail-buzz/cLG5aNdR3qg">Beyond Meat Stock Skyrockets 60% Today: Meme Stock Frenzy Intensifies After ETF Inclusion Amid Surging Retail Buzz</a>

The Krispy Kreme corporate logo is displayed on a sign at their store on January 31, 2025 in San Diego, California. (Photo by Kevin Carter/Getty Images)

DNUT Stock Trades Above 200-DMA For The First Time Since November 2024

Morgan Stanley kept its ‘Underweight’ rating and $2.5 price target on Krispy Kreme.

<ul class="summary-bullets"><li>Beyond Meat stock experienced a 200% increase in retail user messages on Stocktwits.</li><li>Roundhill Investments said that Beyond Meat has been added to the Roundhill Meme Stock ETF.</li><li>Retail sentiment on Beyond Meat remained unchanged in the ‘extremely high’ territory.</li></ul>Beyond Meat (BYND) saw a nearly 200% surge in retail user messages on Stocktwits over the last 24 hours, with its shares jumping over 60% in early trading on Wednesday, mirroring a meme-stock rally following its addition to the Roundhill Meme Stock ETF (MEME).Retail sentiment on <a href="https://stocktwits.com/symbol/BYND">Beyond Meat</a> remained unchanged in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.<h2 class="st-heading-2">Retail Users’ Take On The Stock Surge</h2>A bullish user on Stocktwits noted that the stock could surpass the $10 mark.<stembedurl>https://stocktwits.com/MarketWhispererr/message/633216899</stembedurl>Another user said that Beyond Meat was mirroring GameStop.<stembedurl>https://stocktwits.com/InvestingCat/message/633216438</stembedurl><h2 class="st-heading-2">Stock Milestones</h2>Beyond Meat’s stock has surged over 1,300% from Thursday’s closing price of $0.52. The stock has been gaining every day since then and hit a high of $7.69 in Wednesday’s trading.Last week, the company announced the early settlement of its previously announced exchange offer for convertible senior notes due 2027.Analysts have noted that the firm’s growth has been impacted by increased competition, adverse shifts in consumer perceptions of the health attributes of Beyond Meat products, and termination fees from co-manufacturers.Shares of Beyond Meat have gained over 43% this year but have declined nearly 13% in the last months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/applied-digital-stock-soars-7-premarket-on-5-b-ai-factory-lease/cLG5JkyR3q7">Applied Digital Stock Soars 7% Pre-Market On $5B AI Factory Lease With US Hyperscaler</a>

A group of bondholders of Beyond Meat are reportedly working with the company’s law firm for a possible restructuring.

Beyond Meat Stock Skyrockets 60% Today: Meme Stock Frenzy Intensifies After ETF Inclusion Amid Surging Retail Buzz

Roundhill Investments said that Beyond Meat has been added to the Roundhill Meme Stock ETF.

Praxis Precision Medicines, Inc. (PRAX) announced on Thursday that patients with essential tremor treated with Ulixacaltamide in a late-stage study showed improvement in functional independence.A 4.3 point mean improvement in the Modified Activities of Daily Living 11 (mADL11) score was observed at week 8 in the trial, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-topline-results-1">said</a>. The score is used to assess a person's functional independence and evaluate a person’s ability to do day-to-day activities. Furthermore, the effect was sustained from week 2 throughout the 12-week dosing period, it added.Essential Tremor is the most common movement disorder, affecting roughly seven million people in the U.S. alone, according to Praxis. It is characterized by involuntary rhythmic movement in the upper limbs, with or without tremor in other body locations such as the head, vocal cords, or legs.Praxis now plans to submit an application to the U.S. Food and Drug Administration for approval of Ulixacaltamide in essential tremor by early 2026. Shares of the company rallied 76% in the pre-market session at the time of writing.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PRAX">PRAX stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory, while message volume increased from ‘low’ to ‘extremely high’ levels.The company said that Ulixacaltamide was generally well-tolerated over 12 weeks of treatment, and no deaths or drug-related serious adverse events were recorded. However, discontinuations in the study were 35.6% in patients who received Ulixacaltamide as compared to 5.6% in patients who received placebo, and most discontinuations were primarily due to treatment-emergent adverse events, it said.The company also conducted another late-stage trial where patients showed superior maintenance of effect while on Ulixacaltamide versus placebo after blinded exposure for 8 weeks with Ulixacaltamide.PRAX stock is down by 25% this year and by about 23% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alibaba-executive-reportedly-says-company-beginning-to-see-return-on-ai-investment-in-e-commerce/ch6pRcFR3nf">Alibaba Executive Reportedly Says Company Beginning To See Return On AI Investment In E-Commerce: Forecasts ‘Very Significant’ Positive Impact</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did Praxis Precision Medicines Stock Surge 69% In Pre-Market Today?

The company plans to submit an application to the U.S. Food and Drug Administration for approval of Ulixacaltamide in essential tremor by early 2026.

Candel Therapeutics (CADL) on Tuesday said that it has entered into a five-year, $130 million term loan facility with Trinity Capital (TRIN).The loan facility <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/14/3166168/0/en/Candel-Therapeutics-Enters-into-130-Million-Term-Loan-Facility-with-Trinity-Capital-Inc.html">comprises</a> four tranches. While the first tranche of $50 million will be drawn upon closing of the agreement, the second and third tranche totaling $50 million will be available to draw on the achievement of certain milestones, and the fourth tranche of $30 million will be available at the lender’s discretion, the company said. The loan facility has a five-year term with an interest-only period of 36 months, extendable for an additional 12 months upon achievement of a certain commercial milestone.Proceeds from the loan will be used to refinance certain loan and security agreements, as working capital, and to fund general corporate purposes. The company also said it intends to use the proceeds towards the initiation of a pivotal phase 3 clinical trial of its lead candidate CAN-2409 in non-small cell lung cancer in the second quarter of 2026.Candel Therapeutics shares traded 7% lower on Tuesday morning. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CADL">CADL stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.Candel CFO Charles Schoch said that the strategic financing, in addition to the company’s cash and cash equivalents of $87.2 million as of September 30, strengthens the company’s balance sheet and is also expected to support the company through CAN-2409’s potential launch in early localized prostate cancer and into commercialization.The company plans to submit an application to the U.S. Food and Drug Administration (FDA) for the approval of CAN-2409 for prostate cancer in the fourth quarter of 2026.CADL stock is down by 31% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-major-shareholder-calls-for-sale-of-company-to-larger-pharma-entity/ch6moRsR3mh">Novavax Major Shareholder Calls For Sale Of Company To Larger Pharma Entity</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Candel Therapeutics Enters $130M Term Loan Facility To Advance Lead Product Candidate In Treatment Of Lung Cancer 

The company said that the loan facility has a five-year term with an interest-only period of 36 months, extendable for an additional 12 months upon achievement of a certain commercial milestone.

SELLAS Life Sciences Group (SLS) announced on Monday that preclinical data support its SLS009 as a monotherapy or in combination with Venetoclax for treating a rare and highly aggressive form of mature T-cell leukemia.The biopharmaceutical company said that data supporting the drug in T-cell prolymphocytic leukemia will be presented at the European Society for Medical Oncology Congress 2025, being held October 17 to October 21, in Berlin, Germany. T-PLL or T-cell prolymphocytic leukemia is a rare, aggressive type of mature T-cell leukemia that primarily affects older adults, characterized by the rapid growth of cancerous T-cells.SELLAS <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.sellaslifesciences.com/news/News-Details/2025/SELLAS-Life-Sciences-to-Present-In-Vivo-Preclinical-Data-Demonstrating-Statistically-Significant-Survival-Benefit-of-SLS009-in-T-Cell-Prolymphocytic-Leukemia-at-the-European-Society-for-Medical-Oncology-ESMO-Congress-2025/default.aspx">said</a> that in a study model, SLS009 monotherapy and the combination prolonged overall survival compared to Venetoclax alone, with a statistically significant difference. The combination regimen, which prolonged overall survival to 7.9 weeks, was also well tolerated in the study, the company said.Chief Development Officer at SELLAS, Dragan Cicic, said that the results from the study are “highly encouraging” and noted that T-PLL has minimal treatment options.SLS shares traded 5% higher at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SLS">SLS stock</a> remained in the ‘bullish’ territory, while message volume increased from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:622/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_13_at_11_30_56_AM_png_b0f4827381.webp" alt="SLS's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Oct. 13, 2025 | Source: Stocktwits" width="622" height="61"><figcaption>SLS's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Oct. 13, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user wondered why the stock didn’t rally further on the news.<stembedurl>https://stocktwits.com/SunnySeed/message/632108231</stembedurl>SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications.SLS stock has nearly doubled this year and is up about 60% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/whats-driving-the-rally-in-ndra-stock-today/ch6Sk9VR3kY">What’s Driving The Rally In NDRA Stock Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

SELLAS Life Sciences Stock Rises On Strong Preclinical Data For Investigational Cancer Treatment

SELLAS said that in a study model, SLS009 monotherapy and the combination prolonged overall survival compared to Venetoclax alone, with a statistically significant difference.

Should Vanguard Russell 2000 Growth ETF (VTWG) Be on Your Investing Radar?

A White House official reportedly stated on Monday that the Trump administration was not evaluating a deal to acquire a stake in Critical Metals Corp (CRML) following a Reuters report that the government was considering such a move, which sparked a surge in the rare earths company's stock.Shares of Critical Metals still traded over 46% higher in afternoon trading on Monday. According to a Bloomberg News report, a White House official stated that the administration was in regular contact with the private sector and had received hundreds of deal proposals involving equity stakes.The report added that no active discussions were underway regarding a deal with Critical Metals, which is involved in Greenland’s largest rare earths project. The Reuters report noted that the U.S. was aiming to secure access to Greenland’s Tanbreez project, which Critical Metals acquired last year for $5 million in cash and $211 million in stock.Retail sentiment on <a href="https://stocktwits.com/symbol/CRML">Critical Metals</a> remained unchanged in the ‘extremely bullish’ territory compared to a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.Bloomberg reported that U.S. President Donald Trump has unveiled several agreements in recent months, in which companies have traded equity stakes in return for access to government loans and subsidies. The report added that last month, the U.S. took a 5% stake in Lithium Americas and announced the Vancouver-based company could draw on a previously agreed-upon $2.23 billion loan. In August, Intel Corp announced that the U.S. government would take a 9.9% stake in the firm for $8.9 billion.Critical Metal shares have gained nearly 75% this year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/dollar-tree-shares-dip-after-bernstein-cuts-price-target/ch6RJjIR3g8">Dollar Tree Shares Dip After Bernstein Cuts Price Target On EBIT Performance</a>

U.S. President Donald Trump announces a deal with Pfizer to lower Medicaid drug prices in the Oval Office of the White House on September 30, 2025 in Washington, DC. (Photo by Win McNamee/Getty Images)

White House Reportedly Denies Plans To Acquire Stake In Critical Metals

According to a Bloomberg News report, there were no active discussions underway regarding a deal with Critical Metals, which is involved in Greenland’s largest rare earths project.

Harrow (HROW) announced on Friday that it has entered into an agreement to acquire privately held Melt Pharmaceuticals for an undisclosed price.While Harrow is a provider of ophthalmic disease management solutions, Melt Pharmaceuticals is focused on developing non-opioid therapies for sedation during medical procedures. Melt was spun out of Harrow in January 2019.The acquisition will <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.harrow.com/news-releases/news-release-details/harrow-acquire-melt-pharmaceuticals">include</a> Melt’s lead investigational therapy, MELT-300, a sublingually delivered formulation of a fixed dose of Midazolam (3mg) and Ketamine (50mg) designed to provide rapid, predictable sedation and analgesia without the need for intravenous administration.Shares of Harrow jumped 4% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HROW">HROW stock</a> stayed within ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.MELT-300 was found to be statistically superior to both sublingual Midazolam alone and placebo in providing successful procedural sedation in a late-stage study. A recently completed cardiac safety study also indicated that MELT-300 did not alter normal heart rhythm, supporting the therapy’s safety profile. Harrow now plans to submit a new drug application to the U.S. Food and Drug Administration for the sedative in 2027, and is eyeing a commercial launch in the U.S. in 2028.If the FDA approves MELT-300, the company intends to discontinue the MKO Melt sedation product, marketed through its ImprimisRx subsidiary, for cataract surgeries. The company also sees potential for MELT-300 to be used in other procedures, including claustrophobia during MRIs, sedation for colonoscopies, dental procedures, gastroenterology procedures, and other interventions.The closing of the merger transaction, however, is subject to customary closing conditions, including approval by Melt shareholders, Harrow added.HROW stock is up 43% this year and by about 9% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/costco-draws-mixed-reactions-from-wall-street-despite-q4-beat-here-is-why/chDVjZGR3eX">Costco Draws Mixed Reactions From Wall Street Despite Q4 Beat: Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Harrow To Acquire Sedation Solutions Developer Melt Pharmaceuticals – More Details Inside

The acquisition will include Melt’s lead investigational therapy, MELT-300, designed to provide rapid, predictable sedation and analgesia without the need for intravenous administration. 

Capricor Therapeutics (CAPR) said on Thursday that it expects to submit fresh trial data to the U.S. Food and Drug Administration to get its Deramiocel therapy approved in the treatment of Duchenne muscular dystrophy.The FDA <a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-plunges-after-us-fda-declines-approval-for-muscular-disorder-therapy/ch8cfZ4R5Zn">stated</a> in July that it was unable to approve the application for Deramiocel in its current form as it does not meet the requirement for substantial evidence of effectiveness, and expressed the need for additional clinical data.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/326/capricor-therapeutics-provides-regulatory-update-on">stated</a> on Thursday that it held a meeting with the agency and hopes to submit data from its HOPE-3 late-stage clinical trial as part of its current application. Topline data from the trial, which will serve as the additional study requested by the agency, is expected in the fourth quarter.Shares of the company rose 5% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.“The FDA remains committed to collaborating with the applicant and will exercise further regulatory flexibility by reviewing data from the HOPE-3 trial,” the FDA said in a meeting with the company.“With HOPE-3 completed and data expected later this year, we remain confident in our ability to advance Deramiocel toward potential approval,” CEO Linda Marbán said.The company also stated that it maintains a “strong financial position” to support the advancement of Deramiocel through regulatory review and toward a potential launch for treating Duchenne Muscular Dystrophy (DMD).DMD is a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. The disease affects approximately 15,000 individuals in the United States and primarily impacts boys.CAPR stock is down by about 55% this year and by about 40% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bristol-myers-to-sell-plaque-psoriasis-drug-for-over-80-percent-discount-starting-2026/chDlId9R34B">Bristol Myers To Sell Plaque Psoriasis Drug For Over 80% Discount Starting In 2026</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Capricor Stock Rises Pre-Market Over Fresh Hopes Of Deramiocel Approval In Treating Genetic Disorder

The company announced on Thursday that it held a meeting with the agency and plans to submit data from its HOPE-3 clinical trial as part of its current application.

VTWG
Vanguard Russell 2000 Growth ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest VTWG News

VTWGVanguard Russell 2000 Growth ETF